Jan Aushadhi Kendras Schemes

I have enough Tier-1 facts. Writing the note now.

Jan Aushadhi Kendras Schemes — UPSC Study Note

1. At a Glance

• Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is the umbrella scheme; Jan Aushadhi Kendras (JAKs) are its dedicated retail outlets selling unbranded quality generic medicines at 50%–80% below branded MRP [S1].
• Run by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, via implementing agency Pharmaceuticals & Medical Devices Bureau of India (PMBI) [S1][S3].
• Examinable as a flagship affordable healthcare / out-of-pocket expenditure reduction scheme overlapping GS-II (health governance) and GS-III (pharma sector, MSME entrepreneurship).

2. Why in the News

• Janaushadhi Saptah 2026 (1–7 March 2026) — week-long outreach culminating in the 8th Janaushadhi Diwas on 7 March, with health camps at 250+ locations [S3].
• PIB release (6 Feb 2026) reiterated product basket of 2,110 medicines + 315 surgicals/consumables/devices and the 25,000-Kendra target by 31 March 2027 [S1][S2][S4].

3. Background & Evolution

• Launched in 2008 as Jan Aushadhi Campaign by Dept. of Pharmaceuticals; relaunched and rebranded as PMBJP in 2015–16 with expanded scope [S1].
• Implementing arm reconstituted as PMBI (earlier BPPI — Bureau of Pharma PSUs of India), a society under Dept. of Pharmaceuticals [S1].
• 2022: Online applications invited to open Kendras in 3,579 blocks across 406 districts of 26 States/UTs [S5].
• 16,912 JAKs operational by 30 June 2025; >18,000 by March 2026 [S4][S3].

4. Core Static Facts

• Nodal Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals [S1].
• Implementing Agency: PMBI (Pharmaceuticals & Medical Devices Bureau of India), a registered society [S3].
• Portal: www.janaushadhi.gov.in [S3].
• Product basket: 2,110 generic medicines + 315 surgicals/consumables/devices, covering 29 therapeutic categories (cardiovascular, anti-diabetic, anti-cancer, anti-infective, anti-allergic, GI, nutraceuticals) [S1][S3].
• Price discount: 50%–80% below branded equivalents [S1].
• Target: 25,000 Kendras by 31 March 2027 [S4].
• Eligibility to open JAK: individuals (pharmacist preferred), NGOs, societies, trusts, SHGs, hospitals, private entities [S3].
• Incentives: enhanced support for women, Divyang, SC/ST entrepreneurs and those in Aspirational Districts, North-East, Himalayan & Island territories [S3].

5. Multi-Dimensional Analysis

Economic / Health-Financing - Targets India's high out-of-pocket expenditure (~48% of health spend; medicines the largest component) by substituting branded generics with unbranded generics at fraction price [S1]. - Achieved ₹1,000 cr sales milestone in FY 2023-24, signalling scale economies and reduced drug bill [S5].

Social Equity - Targeted Kendras in Aspirational Districts, NE, Himalayan, Island regions correct urban-rural and regional access gaps [S3]. - Affirmative incentives for women/SC/ST/Divyang entrepreneurs link affordable drugs with livelihood creation [S3].

Administrative / Federalism - Franchise-cum-PPP retail model; online application centrally processed by PMBI — bypasses state licensing delays [S3]. - Railways MoU (2023) to open PMBJKs at select railway stations — inter-ministerial expansion [S6].

Scientific / Quality Assurance - All PMBJP drugs procured only from WHO-GMP & GLP-certified suppliers; tested at NABL-accredited labs before dispatch [S2].

Ethical / Governance - Counters branded-generic price arbitrage and tackles physician prescription bias toward brands — links to NMC's ethical prescription guidelines.

6. Recent Developments (12–18 months)

• 6 Feb 2026 PIB: product basket confirmed at 2,110 + 315 items [S1].
• 1–7 March 2026: Janaushadhi Saptah — 250+ health camps; 8th Janaushadhi Diwas on 7 March [S3].
• Mar 2026: Network crosses 18,000 JAKs en route to 25,000 by March 2027 [S3].
• 30 Jun 2025: Cumulative count 16,912 JAKs [S4].
• 2023 MoU with Ministry of Railways for station-based PMBJKs [S6].

7. Prelims Hooks

• PMBJP launched (relaunched) in 2008; revamped 2015–16 [S1].
• Nodal Dept.: Department of Pharmaceuticals under Ministry of Chemicals & Fertilizers — NOT Ministry of Health [S1].
• Implementing agency: PMBI (formerly BPPI) [S3].
• Janaushadhi Diwas observed on 7 March annually [S3].
• Product basket: 2,110 medicines + 315 surgicals/devices [S1].
• Pricing: 50–80% cheaper than branded equivalents [S1].
• Target: 25,000 Kendras by 31 March 2027 [S4].
• 16,912 JAKs by 30 June 2025; >18,000 by March 2026 [S4][S3].
• Covers 29 therapeutic categories [S3].
• Special incentives in Aspirational Districts, NE, Himalayan & Island regions [S3].
• Application portal: janaushadhi.gov.in [S3].
• Crossed ₹1,000 cr in sales in FY 2023-24 [S5].

8. Mains Relevance

• GS-II: Welfare schemes for vulnerable sections; Issues relating to development and management of Health.
• GS-III: Indian pharmaceutical sector; inclusive growth.
• Possible stems: 1. "Jan Aushadhi Kendras have the potential to dent India's high out-of-pocket health expenditure but face acceptance and supply-chain hurdles. Examine." (GS-II) 2. "Discuss the role of generic medicines in achieving Universal Health Coverage in India, with reference to PMBJP." (GS-II) 3. "Evaluate PMBJP as a model of welfare-cum-entrepreneurship." (GS-III)

9. Related Topics to Study Next

• Ayushman Bharat (PM-JAY) — complementary OOP-reduction tool.
• National Health Mission / NHA — health system delivery backbone.
• Drugs Price Control Order (DPCO) & NPPA — price-cap regulator for essential drugs.
• NLEM (National List of Essential Medicines) 2022 — overlaps with PMBJP basket.
• Indian Pharmaceutical Sector / PLI for pharma & bulk drugs — supply side.
• Universal Health Coverage / SDG 3 — global benchmark.
• Ayushman Bharat Digital Mission (ABDM) — e-pharmacy linkages.
• CDSCO & WHO-GMP standards — quality regulation backbone.

10. Common Errors / Trap Areas

• Wrong ministry: it is Chemicals & Fertilizers (Dept. of Pharmaceuticals), NOT Ministry of Health & Family Welfare.
• Confusing PMBI with BPPI (BPPI was the predecessor body) or with NPPA (NPPA is a price regulator, not implementing agency).
• Janaushadhi Diwas is 7 March, not 1 March (Saptah begins 1 March).
• "Generic" here means unbranded generic — distinct from "branded generics" sold by Indian pharma firms.
• PMBJP is not part of Ayushman Bharat; they are parallel schemes.
• Number traps: 2,110 medicines + 315 surgicals (not 2,000/300); 25,000 by March 2027 (not 2025).

11. Sources

• [S1] Jan Aushadhi Kendras Schemes (PIB, 6 Feb 2026) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2224371 — (tier: 1)
• [S2] Annexure: list of 2110 generic medicines under PMBJP till 31.12.2025 — https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/feb/doc202626781701.pdf — (tier: 1)
• [S3] Janaushadhi Saptah 2026 kicks off with Health Camps across the Country — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2234273&reg=3&lang=2 — (tier: 1)
• [S4] 16,912 JAKs opened till 30.6.2025; target 25,000 by March 2027 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2149782&reg=3&lang=2 — (tier: 1)
• [S5] PMBJP achieves ₹1,000 Cr sales target in FY 2023-24 — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=1988675 — (tier: 1)
• [S6] Ministry of Railways to establish PMBJKs at railway stations — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=1947751 — (tier: 1)